Semaglutide has become one of the most discussed medications in recent years. It is used for the management of type 2 diabetes and, at specific doses, as a medical option for obesity or overweight. Its effects on appetite, body weight, and glucose control have generated significant interest, but they have also raised important questions about long-term safety.
One of the most common concerns is whether semaglutide, or GLP-1 receptor agonists in general (a drug class that includes medications such as Ozempic and Wegovy) could be linked to cancer. This is a valid question, especially because these treatments may be used for months or years and act on important metabolic pathways.
Why Is Semaglutide So Widely Discussed?
GLP-1 is a natural hormone involved in blood sugar regulation, insulin secretion, satiety, and gastric emptying. Semaglutide works by mimicking this signal and activating the GLP-1 receptor, helping improve glucose control and, in many patients, supporting significant weight loss.
This matters because obesity and type 2 diabetes are not isolated metabolic conditions. Both are associated with low-grade chronic inflammation, insulin resistance, hormonal changes, and alterations in the cellular microenvironment. These processes may influence, directly or indirectly, the risk of certain types of cancer.
For this reason, the discussion around semaglutide and cancer has two sides. On one hand, researchers ask whether the medication could increase any specific cancer risk. On the other, they also examine whether improving body weight and metabolic health could reduce biological factors associated with tumor development.
Why Did Concerns About Cancer Arise?
The main concern has historically focused on the thyroid, particularly a rare tumor called medullary thyroid carcinoma. This concern originated from animal studies in which some GLP-1 receptor agonists were associated with tumors in thyroid cells.
However, findings in rodents cannot be automatically translated to humans. Thyroid cells do not behave exactly the same way across species, and GLP-1 receptor expression may vary between rodents and humans. Therefore, while the warning should be taken seriously, it does not mean that every person using semaglutide has a high risk of developing thyroid cancer.
The pancreas has also been part of the debate, since GLP-1 receptor agonists act on pathways related to pancreatic function, insulin, glucagon, and glucose metabolism. This concern has led to multiple studies evaluating whether there is a real cancer signal in humans.
A 2023 meta-analysis evaluated 37 randomized clinical trials and 19 observational studies, focusing on thyroid cancer, pancreatic cancer, and overall neoplasms. The main finding was reassuring: semaglutide was not associated with a significant increase in cancer risk based on the available data.
This does not mean that medical surveillance is no longer necessary. It means that, so far, there is no strong signal indicating that semaglutide clearly increases the overall risk of cancer in humans.
Thyroid Cancer
The thyroid remains one of the most closely monitored organs in this discussion. Although human studies have not consistently confirmed a major increase in risk, medications in this family still carry warnings for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, known as MEN2.
A Scandinavian study published in *BMJ* evaluated GLP-1 receptor agonist use and thyroid cancer risk and found no substantial increase over an average follow-up of 3.9 years. In addition, the European Medicines Agency reviewed the available evidence and concluded that the data did not support a causal association between GLP-1 receptor agonists — including semaglutide — and thyroid cancer.
Even so, the clinical recommendation remains clear: people with a personal or family history of medullary thyroid carcinoma or MEN2 should discuss the use of these medications carefully with their physician.
Pancreatic Cancer
The pancreas has also been studied closely because GLP-1 receptor agonists influence pathways involved in insulin, glucagon, and glucose metabolism. For years, researchers have investigated whether these medications could be associated with pancreatitis or pancreatic cancer.
For semaglutide specifically, the 2023 meta-analysis did not find a significant increase in pancreatic cancer. This is an important finding because pancreatic cancer is an aggressive disease, and any possible risk signal must be evaluated carefully.
Still, the absence of a clear signal does not mean symptoms should be ignored. Persistent or severe abdominal pain, intense nausea, ongoing vomiting, or concerning digestive symptoms should be evaluated by a healthcare professional, especially in people with a history of pancreatitis or other pancreatic risk factors.
The Other Side: Obesity, Diabetes, and Cancer Risk
To understand this topic properly, it is important to remember that obesity is associated with a higher risk of several cancers, including colorectal, endometrial, liver, kidney, pancreatic, gallbladder, and some hormone-related tumors. This relationship is explained by several mechanisms, including chronic inflammation, insulin resistance, hormonal alterations, oxidative stress, and changes in adipose tissue biology.
For that reason, GLP-1 receptor agonists are not only being studied from a safety perspective. Researchers are also exploring whether these medications could reduce some obesity-related cancer risks by improving weight, glucose control, and inflammatory markers.
A study published in JAMA Network Open in 2024 evaluated GLP-1 receptor agonists in patients with type 2 diabetes and found that these medications were associated with a lower risk of some obesity-related cancers.
More recently, a study published in Annals of Oncology in 2026 analyzed adults with obesity but without diabetes using a method called target trial emulation. This approach uses real-world data to approximate the design of a clinical trial. The study included more than 229,000 patients and, after statistical matching, compared 80,899 users of GLP-1 receptor agonists with 80,899 people who received diet or exercise counseling.
During a median follow-up of 2 years, GLP-1 receptor agonist users had a lower incidence of obesity-associated cancers. In simple terms, this suggested an approximate 41% relative reduction in the incidence of these cancers among treated patients.
Figure 1. Semaglutide acts on GLP-1–related metabolic pathways that regulate appetite, glucose control, and weight loss, while obesity may influence cancer risk through chronic inflammation, insulin resistance, hormonal imbalance, and altered adipose tissue signaling.
So, Does Semaglutide Increase or Reduce Cancer Risk?
The most accurate answer is that, based on current evidence, semaglutide does not appear to significantly increase overall cancer risk. At the same time, emerging studies suggest that GLP-1 receptor agonists may be associated with a lower incidence of certain obesity-related cancers, likely through improvements in weight, metabolism, and inflammation.
However, semaglutide should not be understood as an anticancer medication. Its possible association with lower cancer incidence appears to be related to its impact on obesity and metabolic risk factors, not because it directly treats or prevents cancer. Therefore, the central message remains the importance of healthy lifestyle habits, including regular weight management, balanced nutrition, physical activity, and medical follow-up.
Conclusion
The relationship between semaglutide, GLP-1 receptor agonists, and cancer is still evolving. Current studies do not show a significant increase in overall cancer risk with semaglutide, and the evidence regarding thyroid and pancreatic cancer is generally reassuring. At the same time, recent research suggests that these medications may be associated with a lower incidence of some cancers related to obesity.
The key is to avoid oversimplifying the message. Semaglutide should not be presented as a proven cause of cancer, nor as a therapy to prevent it. It is a metabolic medication with important benefits in selected patients, while its long-term oncologic impact continues to be studied. As always, the best decision should be individualized, informed, and guided by a healthcare professional.
This article is intended for educational and informational purposes only. It does not replace professional medical advice, diagnosis, or treatment.
Main reference:
Nagendra, L., Bg, H., Sharma, M., & Dutta, D. (2023). Semaglutide and cancer: A systematic review and meta-analysis. Diabetes & metabolic syndrome, 17(9), 102834. https://doi.org/10.1016/j.dsx.2023.102834
Other references:
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025). GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials. Diabetes, obesity & metabolism, 27(8), 4454–4468. https://doi.org/10.1111/dom.16489
Dai, H., Li, Y., Lee, Y. A., Lu, Y., George, T. J., Donahoo, W. T., Lee, K. P., Nakshatri, H., Allen, J., Guo, Y., Sun, R. C., Guo, J., & Bian, J. (2025). GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. JAMA oncology, 11(10), 1186–1193. https://doi.org/10.1001/jamaoncol.2025.2681
